

# PRECEPTORSHIP PROGRAMME

## Gastric Cancer

**ESMO  
PRECEPTORSHIP**

**SINGAPORE  
30 NOVEMBER - 1 DECEMBER  
2022**

Multidisciplinary management, standards of care, therapeutic targets and future perspectives.

**Chairs:**

Florian Lordick, Germany

Matthew C. H. Ng, Singapore

# ESMO PRECEPTORSHIP PROGRAMME GASTRIC CANCER

Multidisciplinary management, standards of care and future perspectives

Singapore

30 November -1 December 2022

**CO-CHAIRS:** Florian Lordick, Germany  
Matthew C. H. Ng, Singapore

**SPEAKERS:** Claramae S. Chia, Singapore  
Hanneke van Laarhoven, Netherlands  
Tony K. H. Lim, Singapore  
Brigette Ma, Hong Kong  
Joanne Y. Y. Ngeow, Singapore  
Radka Obermannová, Czech Republic  
Raghav Sundar, Singapore  
Sun Young Rha, South Korea  
Jimmy B. Y. So, Singapore  
Wei Peng Yong, Singapore

## LEARNING OBJECTIVES

- To learn the fundamental of epidemiology, aetiology, pathogenesis, molecular events, and ethnic patterns as contributing factors to heterogeneity in gastric cancer (GC)
- To understand the importance of pathology and molecular factors
- To learn about best clinical practice in the multidisciplinary management of gastric and gastro-esophageal junction (GEJ) and esophageal squamous cell cancers in the adjuvant and metastatic settings
- To learn about current best practice for endoscopic and surgical resection of localized gastric cancer
- To be able to compare the benefits of neo-adjuvant, adjuvant approaches and the value of radiotherapy in the management of localized gastro-esophageal cancers
- To learn about the management of patients after progression, in special situations and side effects of treatments
- To learn about the advances in the treatment and novel targets in gastric cancer

## ACCREDITATION

The programme of this event has been accredited with **8 ESMO-MORA category 1 points**.  
Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to [esmo.org](http://esmo.org).

## ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



## ORGANISATION AND CONTACTS

ESMO Head Office  
Education Department  
Via Ginevra 4, 6900 Lugano, Switzerland  
Email: [courses@esmo.org](mailto:courses@esmo.org)  
[www.esmo.org](http://www.esmo.org)



## Wednesday, 30 November 2022

<b>9:00-9:10</b> <b>10'</b>	<b>Welcome and introduction</b>	<b>Florian Lordick, DE</b> <b>Matthew C. H. Ng, SG</b>
<b>9:10-10:40</b> <b>90'</b>	<b>SESSION 1 – part 1</b> <b>Epidemiology, pathology and multidisciplinary management of localized gastric cancer</b>	<b>Chair:</b> <b>Matthew C. H. Ng, SG</b>
25'	Epidemiology, pathogenesis and molecular subtypes	Brigette Ma, HK
25'	How pathology can guide treatment: HER2, MSI, PDL1 and EBV	Tony K. H. Lim, SG
25'	Approaches to investigate heterogeneity in gastric cancer	Raghav Sundar, SG
15'	Discussion	Faculty
<b>10:40-11:10</b>	<b>Coffee break</b>	
<b>11:10-12:40</b> <b>90'</b>	<b>SESSION 1 – part 2</b> <b>Epidemiology, pathology and multidisciplinary management of localized gastric cancer</b>	<b>Chair:</b> <b>Brigette Ma, HK</b>
25'	A practical approach to hereditary gastric cancers	Joanne Y. Y. Ngeow, SG
25'	Advances in surgery: endoscopic, minimally invasive, optimal nodal dissection and organ-sparing (spleen, omentum)	Jimmy B. Y. So, SG
25'	Neo- and adjuvant approaches to GC	Matthew C. H. Ng, SG
15'	Discussion	Faculty
<b>12:40-13:40</b>	<b>Lunch</b>	
<b>13:40-14:45</b> <b>65'</b>	<b>SESSION 1 – part 3</b> <b>Epidemiology, pathology and multidisciplinary management of localized gastric cancer</b>	<b>Chair:</b> <b>Florian Lordick, DE</b>
25'	Neo-adjuvant chemo or chemoradiation for Type1/2 GEJ cancer and novel study concepts in the localized setting	Florian Lordick, DE
25'	ESMO Guidelines for esophageal cancer and new data on treatment of stage IV esophageal cancer	Radka Obermannová, CZ
15'	Discussion	Faculty
<b>14:45-15:15</b>	<b>Coffee break</b>	
<b>15:15-16:30</b> <b>75'</b>	<b>SESSION 2</b> <b>Participants clinical case discussion</b>	<b>Chair:</b> <b>Florian Lordick, DE</b>
75'	Participants clinical case discussion (5x15') ( <i>localized disease</i> )	Faculty
<b>18:00</b>	<b>Networking Cocktail Reception</b>	

Thursday, 1 December 2022

<b>9:00-11:35</b> <b>125'</b>	<b>SESSION 3</b> <b>Metastatic gastric cancer</b>	<b>Chair:</b> <b>Sun Young Rha, KR</b>
25'	Optimizing chemotherapy and molecularly targeted therapy	Wei Peng Yong, SG
25'	Immunotherapy monotherapy or in combination and when best to give it	Sun Young Rha, KR
10'	Discussion	Faculty
<b>10:00-10:30</b>	<b>Break</b>	
25'	Approaches to treat oligometastatic disease	Hanneke van Laarhoven, NL
25'	Intraperitoneal therapy for peritoneal limited gastric cancer	Claramae S. Chia, SG
15'	Discussion	Faculty
<b>11:35-12:35</b> <b>60'</b>	<b>SESSION 4</b> <b>Participants clinical case discussion</b>	<b>Chair:</b> <b>Matthew C. H. Ng, SG</b>
60'	Participants clinical case discussion (4x15') ( <i>advanced disease</i> )	Faculty
<b>12:35-12:40</b> <b>5'</b>	<b>Conclusion and farewell</b>	<b>Florian Lordick, DE</b> <b>Matthew C. H. Ng, SG</b>
<b>12:40-13:40</b>	<b>Lunch</b>	

**Note:** Each 15-minute slot for clinical case discussion includes 7' case presentation and 8' Q&A / panel discussion